This meta-analysis aims at evaluating the relationships between CYP1A1 genetic polymorphisms and bladder cancer risk. The PubMed, CISCOM, CINAHL, Web of Science, Google Scholar, EBSCO, Cochrane Library, and CBM databases were searched from inception through November 1st, 2013 without language restrictions. Meta-analysis was conducted with the use of the STATA 12.0 software. The relationships were evaluated by calculating the pooled odds ratios (ORs) and their 95% confidence intervals (CIs). Eight case-control studies with a total of 2120 bladder cancer patients and 2061 healthy subjects met the inclusion criteria. Ten common polymorphisms in the CYP1A1 gene were assessed. The results of our meta-analysis suggested that CYP1A1 genetic polymorphisms might be strongly correlated with an increased risk of bladder cancer (allele model: OR=1.23, 95%CI=1.08–1.39, p=0.001; dominant model: OR=1.25, 95%CI=1.07–1.46, p=0.005; respectively), especially for 11599G>C, 2455A>G, 3810T>C, and 113T>C polymorphisms. A subgroup analysis was done to investigate the effect of ethnicity on an individual's risk of bladder cancer. Our results revealed positive significant correlations between CYP1A1 genetic polymorphisms and an increased risk of bladder cancer among Asians (allele model: OR=1.33, 95%CI=1.08–1.65, p=0.009; dominant model: OR=1.37, 95%CI=1.02–1.85, p=0.034; respectively), but not among Caucasians (all p<0.05). Our findings provide convincing evidence that CYP1A1 genetic polymorphisms may contribute to susceptibility to bladder cancer, especially for 11599G>C, 2455A>G, 3810T>C, and 113T>C polymorphisms among Asians.
Get full access to this article
View all access options for this article.
References
1.
AndroutsopoulosV.P., TsatsakisA.M., and SpandidosD.A. (2009). Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer, 9, 187.
2.
BeedanagariS.R., BebenekI., BuiP., and HankinsonO. (2009). Resveratrol inhibits dioxin-induced expression of human CYP1A1 and CYP1B1 by inhibiting recruitment of the aryl hydrocarbon receptor complex and RNA polymerase II to the regulatory regions of the corresponding genes. Toxicol Sci, 110, 61–67.
3.
BerberU., YilmazI., YilmazO., HaholuA., KucukodaciZ., AtesF., et al. (2013). CYP1A1 (Ile462Val), CYP1B1 (Ala119Ser and Val432Leu), GSTM1 (null), and GSTT1 (null) polymorphisms and bladder cancer risk in a Turkish population. Asian Pac J Cancer Prev, 14, 3925–3929.
4.
BrockmollerJ., CascorbiI., KerbR., and RootsI. (1996). Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res, 56, 3915–3925.
5.
CashH.L., TaoL., YuanJ.M., MarsitC.J., HousemanE.A., XiangY.B., et al. (2012). LINE-1 hypomethylation is associated with bladder cancer risk among nonsmoking Chinese. Int J Cancer, 130, 1151–1159.
6.
ChenC.M., JinY.T., XuH.Y., ZhangC.Y., ZhangH., ZhangW.M., et al. (2012). Effects of CYP1A1 and GSTM1 gene polymorphisms and BPDE-DNA adducts on lung cancer. Chin J Med Genet, 29, 23–27.
7.
ChuH., WangM., and ZhangZ. (2013). Bladder cancer epidemiology and genetic susceptibility. J Biomed Res, 27, 170–178.
8.
DelescluseC., LemaireG., de SousaG., and RahmaniR. (2000). Is CYP1A1 induction always related to AHR signaling pathway?. Toxicology, 153, 73–82.
9.
DurocherF., MorissetteJ., and SimardJ. (1998). Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. Pharmacogenetics, 8, 49–53.
10.
FontanaL., DelortL., JoumardL., RabiauN., BosvielR., SatihS., et al. (2009). Genetic polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 genes and association with bladder cancer risk in a French cohort. Anticancer Res, 29, 1631–1635.
11.
FuJ., and ChenB.C. (2013). Relationship between genetic polymorphisms of CYP1A1, NQO1 and EPHX1 and susceptibility to bladder cancer. Chin J Cancer Prev Treat, 20, 10–14.
12.
GrandoJ.P., KuasneH., Losi-GuembarovskiR., Sant'ana RodriguesI., MatsudaH.M., FugantiP.E., et al. (2009). Association between polymorphisms in the biometabolism genes CYP1A1, GSTM1, GSTT1 and GSTP1 in bladder cancer. Clin Exp Med, 9, 21–28.
13.
HungR.J., BoffettaP., BrennanP., MalaveilleC., HautefeuilleA., DonatoF., et al. (2004). GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer, 110, 598–604.
14.
JarukamjornK., KondoS., ChatuphonprasertW., SakumaT., KawasakiY., and NemotoN. (2010). Gender-associated modulation of inducible CYP1A1 expression by andrographolide in mouse liver. Eur J Pharm Sci, 39, 394–401.
15.
JemalA., BrayF., CenterM.M., FerlayJ., WardE., and FormanD. (2011). Global cancer statistics. CA Cancer J Clin, 61, 69–90.
16.
JiangX., CastelaoJ.E., YuanJ.M., SternM.C., ContiD.V., CortessisV.K., et al. (2012). Cigarette smoking and subtypes of bladder cancer. Int J Cancer, 130, 896–901.
17.
KiemeneyL.A., GrotenhuisA.J., VermeulenS.H., and WuX. (2009). Genome-wide association studies in bladder cancer: first results and potential relevance. Curr Opin Urol, 19, 540–546.
18.
KiltieA.E. (2010). Common predisposition alleles for moderately common cancers: bladder cancer. Curr Opin Genet Dev, 20, 218–224.
19.
MasekV., AnzenbacherovaE., EtrychT., StrohalmJ., UlbrichK., and AnzenbacherP. (2011). Interaction of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates with human liver microsomal cytochromes P450: comparison with free doxorubicin. Drug Metab Dispos, 39, 1704–1710.
20.
MohebatiA., GuttenplanJ.B., KochharA., ZhaoZ.L., KosinskaW., SubbaramaiahK., et al. (2012). Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis. Cancer Prev Res (Phila), 5, 593–602.
21.
NukayaM., LinB.C., GloverE., MoranS.M., KennedyG.D., and BradfieldC.A. (2010). The aryl hydrocarbon receptor-interacting protein (AIP) is required for dioxin-induced hepatotoxicity but not for the induction of the Cyp1a1 and Cyp1a2 genes. J Biol Chem, 285, 35599–35605.
22.
OzturkT., KahramanO.T., ToptasB., KisakesenH.I., CakalirC., VerimL., et al. (2011). The effect of CYP1A1 and GSTM1 gene polymorphisms in bladder cancer development in a Turkish population. In Vivo, 25, 663–668.
23.
PetersJ.L., SuttonA.J., JonesD.R., AbramsK.R., and RushtonL. (2006). Comparison of two methods to detect publication bias in meta-analysis. JAMA, 295, 676–680.
24.
PloegM., AbenK.K., and KiemeneyL.A. (2009). The present and future burden of urinary bladder cancer in the world. World J Urol, 27, 289–293.
25.
SridharJ., JinP., LiuJ., ForoozeshM., and StevensC.L. (2010). In silico studies of polyaromatic hydrocarbon inhibitors of cytochrome P450 enzymes 1A1, 1A2, 2A6, and 2B1. Chem Res Toxicol, 23, 600–607.
26.
SrivastavaD.S., MandhaniA., and MittalR.D. (2008). Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India. Arch Toxicol, 82, 633–639.
27.
StangA. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25, 603–605.
28.
StejskalovaL., and PavekP. (2011). The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta. Curr Pharm Biotechnol, 12, 715–730.
29.
SuchockiP., Misiewicz-KrzeminskaI., SkupinskaK., NiedzwieckaK., LubelskaK., FijalekZ., et al. (2010). Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacol Rep, 62, 352–361.
30.
van WaterschootR.A., and SchinkelA.H. (2011). A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. Pharmacol Rev, 63, 390–410.
31.
VillanuevaC.M., SilvermanD.T., Murta-NascimentoC., MalatsN., Garcia-ClosasM., CastroF., et al. (2009). Coffee consumption, genetic susceptibility and bladder cancer risk. Cancer Causes Control, 20, 121–127.
32.
WuX., GuJ., GrossmanH.B., AmosC.I., EtzelC., HuangM., et al. (2006). Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet, 78, 464–479.
33.
YangL.X., ZhangH.F., CuiW.P., and BaiS.F. (2007). Analysis of the polymorphism of CYP1A1-MSPI gene in patients with bladder cancer. China Practic Med, 02, 3–5.
34.
YoungC.H., LoY.L., TsaiY.Y., ShihT.S., LeeH., and ChengY.W. (2010). CYP1A1 gene polymorphisms as a risk factor for pterygium. Mol Vis, 16, 1054–1058.
35.
YousefA.M., BulatovaN.R., NewmanW., HakoozN., IsmailS., QusaH., et al. (2012). Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population. Mol Biol Rep, 39, 9423–9433.
36.
ZintzarasE., and IoannidisJ.P. (2005). HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics, 21, 3672–3673.
